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was signiﬁcantly higher: $8877 versus $7597; P = 0.001. In patients who had a VTE 
event, mean cost of care was almost 26% ($3906) and 17% ($1935) higher for stays 
in short—and long-term facilities, respectively; P = 0.001. On average, Medicare paid 
26% ($4057), 17% ($2102), and 17% ($1149) more due to VTE events for patients 
discharged to a short- or long-term facility or an SNF, respectively. CONCLUSIONS: 
Regardless of discharge status, VTE events during initial hospitalization for THR/TKR 
signiﬁcantly increase total costs of a 1-year stay.
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OBJECTIVES: To evaluate direct costs associated with the use of valsartan/amlodipine 
single pill combination (SPC) therapy versus angiotensin receptor blocker (ARB) plus 
calcium channel blocker (CCB) free combination (FC) therapy in hypertensive 
patients. METHODS: Administrative claims data from the HealthCore Integrated 
Research Database (HIRDTM) were used to identify patients with ≥1 hypertension 
claim (ICD-9 codes 401.xx-404.xx) and ≥1 ﬁll for valsartan/amlodipine SPC or ARB/
CCB FC during the intake period 7/1/2007—9/30/2008. Only patients with ≥6 months 
pre- and post-index health plan eligibility were selected. Total health care costs, 
medical costs and pharmacy costs were aggregated over the follow-up period and 
annualized. Generalized linear models were used to control for baseline differences 
between the SPC and FC therapy groups and to compare annualized total costs, 
medical costs and pharmacy costs between SPC and FC groups, respectively. 
RESULTS: A total of 1,226 patients were identiﬁed in the SPC group and 280 patients 
in the FC group. After controlling for baseline differences, the SPC cohort ($6,402) 
had signiﬁcantly lower total health care costs compared with patients in the FC cohort 
($7,758), p = 0.0096. Similarly, the SPC group had lower medical costs ($4,408 vs. 
$5,517, p = 0.0373) and lower annual pharmacy costs ($1,864 vs. $2,074, p = 0.0417) 
compared to FC patients. CONCLUSIONS: Annual total costs were $1,356 lower for 
patients taking valsartan/amlodipine single pill combination therapy as compared to 
patients taking ARB/CCB free combination therapy, suggesting that treatment of 
hypertensive patients with valsartan/amlodipine single pill combination therapy may 
result in cost savings compared to ARB/CCB free combination therapy.
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OBJECTIVES: To compare compliance/persistence, health care utilization, and costs 
associated with select antihypertensive single-pill combination (SPC) vs. free combina-
tion (FC) therapies among adult hypertension patients at both the national and state 
level. METHODS: Adult hypertension patients initiated on SPC or FC with angioten-
sin receptor blocker (ARB) + calcium channel blocker, ARB + hydrochlorothiazide, 
or angiotensin-converting enzyme inhibitors + hydrochlorothiazide were identiﬁed in 
the MarketScan Database (2006–2008). Study outcomes during the 6-month study 
period included medication possession ratio (MPR), treatment discontinuation rates, 
inpatient and emergency room (ER) visits, and changes in health care costs (study 
period minus baseline). Multivariate regression models examined the effect of SPC (vs. 
FC) use and its regional variation on outcomes, controlling for demographics, comor-
bidities, prescription use, and health care utilization during the baseline period (6 
months pre-therapy initiation). Regression-adjusted differences in outcomes between 
SPC vs. FC patients and associated 95% conﬁdence intervals (CIs) were estimated for 
the average patient in the U.S. and within each state. RESULTS: Adjusting for baseline, 
SPC patients (N = 382,476) demonstrated signiﬁcantly higher MPR (difference = 9.4% 
[95% CI: 9.2%, 9.5%]) and were less likely to discontinue treatment (odds ratio = 
0.535 [95% CI: 0.528, 0.542]) than FC patients (N = 197,375) nationwide. SPC 
patients had signiﬁcantly less hospitalizations and ER visits than FC patients, including 
29% fewer cardiovascular-related hospitalizations (adjusted incidence rate ratio = 0.71 
[95% CI: 0.69, 0.72]). Compared to FC, SPC patients showed signiﬁcantly greater 
reductions post-therapy initiation in all-cause medical costs by −$208 (95% CI: −$302, 
−$114), but larger increases in hypertension-related prescription costs by $53 (95% 
CI: $51, $55). State-level results were generally consistent in magnitude and trend for 
compliance and utilization outcomes, with greater regional variation in costs. CON-
CLUSIONS: SPC was associated with signiﬁcantly better compliance/persistence and 
lower frequencies of hospitalizations and ER visits compared to FC in hypertension 
patients. Larger reductions in medical costs with SPC offset small increases in drug 
costs.
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OBJECTIVES: To compare compliance/persistence, health care utilization, and costs 
associated with aliskiren + ARB vs. ARB + ACEI combination therapies among adult 
patients with hypertension. METHODS: Patients with hypertension (age≥18) initiated 
on combination therapy (≥15 days of overlap) with aliskiren + ARB or ARB + ACEI 
during July 2007-June 2008 were identiﬁed in the MarketScan Database. Study out-
comes were measured during the 6-month study period, including medication posses-
sion ratio (MPR), treatment discontinuation rates, resource utilization, and changes 
in health care costs (from 6-month baseline to study period). Risk-adjusted differences 
in outcomes between aliskiren + ARB vs. ARB + ACEI patients and their 95% conﬁ-
dence intervals (CIs) were estimated using multivariate regression models, controlling 
for demographics, comorbidities, prescription drug use, and health care resource 
utilization during the baseline period. RESULTS: Comorbidity proﬁles were similar 
between patients on aliskiren + ARB (N = 1,395) vs. ARB + ACEI (N = 16,507), 
though baseline resource utilization and costs were different between the cohorts. 
Adjusting for baseline characteristics, aliskiren + ARB patients demonstrated signiﬁ-
cantly higher MPR (difference = 15.2% [95% CI: 13.0%, 17.4%]) and lower discon-
tinuation rate (odds ratio = 0.43 [95% CI: 0.37, 0.51]) than ARB + ACEI patients. 
Aliskiren + ARB patients had fewer all-cause hospitalizations (adjusted incidence rate 
ratio [IRR] = 0.73 [95% CI: 0.61, 0.86]) and fewer all-cause emergency room (ER) 
visits (adjusted IRR = 0.72 [95% CI: 0.61, 0.85]) than ARB + ACEI patients; results 
for cardiovascular-related hospitalizations and ER visits were similar. Compared to 
ARB + ACEI patients, aliskiren + ARB patients had larger increases in prescription 
costs by $264 during the 6 months following therapy initiation (95% CI: $153, $375), 
but showed a trend in reducing total health care costs by −$583 (95% CI: −$2,409, 
$1,242) during the same 6-month period. CONCLUSIONS: Patients with hyperten-
sion initiated on aliskiren + ARB had signiﬁcantly better compliance/persistence and 
lower frequencies of hospitalizations and ER visits than those initiated on ARB + 
ACEI. Trends indicated greater reductions in total health care costs with aliskiren + 
ARB, despite increased prescription costs.
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OBJECTIVES: The incidence and incremental additional cost of surgical site infections 
(SSIs) for common cardiothoracic surgical procedures are not well characterized. Our 
study was designed to estimate the cost of several higher volume inpatient cardiotho-
racic surgical procedures to better characterize the burden of SSIs to hospitals and the 
health care system. METHODS: The Premier Perspective™ Database (PPD) was used 
to estimate the incidence and costs for SSIs in several common cardiothoracic surgical 
procedures using ICD-9 codes discharged between Q2 2006 and Q1 2009 from the 
over 600 US hospitals included in the PPD. PPD is the largest hospital-based, service-
level comparative database in the USA providing detailed resource utilization and cost 
data categorized under a patients’ principal and secondary diagnosis procedure codes. 
Our study focused on high volume cardiothoracic surgical procedures including 
sternum closure (3 codes), CABG (3 codes), and valve replacement (4 codes) to better 
estimate the incidence and costs of SSIs and the added costs to the health care system. 
RESULTS: The incidence of coded SSIs ranged between 1.9% to 6.3%, while the 
incremental additional costs for each SSI ranged between $30,395 and $67,722. The 
magnitude, therefore, of increased costs for each SSI was 2- to 6-fold higher compared 
with not having an SSI, depending on the cardiothoracic surgical procedure. 
CONCLUSIONS: The incidence of SSIs in several common cardiothoracic surgical 
procedures were relatively small (1.9%-6.3%), however, the increased costs ranged 
from 2- to 6-fold higher per SSI representing a substantial economic burden to hos-
pitals in the US health care system. New health care interventions targeted towards 
reducing the incidence of SSIs for common cardiothoracic procedures along the 
patient-care continuum are likely to reduce costs in both the short and long-term for 
hospitals in the US health care system.
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OBJECTIVES: Real world outcomes differences between valvular and non-valvular 
atrial ﬁbrillation is unknown. We identiﬁed these patients from U.S. claims data and 
compared the main outcomes differences to determine the economic and clinical 
burden of the disease. METHODS: We used U.S. medical and pharmacy claims data 
from 2005–2007 for the analysis. Patients aged 65 years and older who have had 2 
or more primary diagnoses for atrial ﬁbrillation occurring within 30 days of one 
